Skip to main content
Erschienen in: International Journal of Hematology 5/2021

15.02.2021 | Original Article

Quality of life and patient-reported outcomes in chronic severe neutropenia conditions

Erschienen in: International Journal of Hematology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Quality of life (QOL) and patient-reported outcomes (PROs) assessments in immunodeficiency patients, including those with chronic severe neutropenia conditions, are imperative to determining modifiable health-related features to optimize care. We present the largest study to date of QOL in those with chronic severe neutropenia conditions with further evaluation of patient provider satisfaction and patient-reported outcome measures. Subjects completed electronic surveys assessing QOL, PROs, and patient provider satisfaction. There is a significantly negative impact of a chronic severe neutropenia disorder on QOL, fatigue, physical function, cognitive function and pain in adult patients when compared to controls. Children with a chronic neutropenia condition had comparable QOL to controls, but reported fewer depressive symptoms, improved mobility, and stronger self-reported peer relationships. Adults had worse scores for QOL, depression and fatigue when compared to children. Adult and pediatric chronic severe neutropenia patients or their caregivers felt that their medical provider was compassionate, trustworthy, and accessible. However, less than 50% of adult patients agreed their clinician had excellent expertise in white blood cell disorders. Chronic neutropenia complexly affect QOL and PROs. An analysis of these parameters allows for targeted interventions to improve patient psychosocial, physical and neurocognitive health.
Literatur
1.
Zurück zum Zitat Quinti I, Pulvirenti F. Health-related quality of life and patients’ empowerment in the health care of primary immune deficiencies. J Clin Immunol. 2017;37:615–6.CrossRef Quinti I, Pulvirenti F. Health-related quality of life and patients’ empowerment in the health care of primary immune deficiencies. J Clin Immunol. 2017;37:615–6.CrossRef
2.
Zurück zum Zitat Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a primary immune deficiency: a systematic synthesis of the literature and proposed research agenda. J Clin Immunol. 2016;36:123–33.CrossRef Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a primary immune deficiency: a systematic synthesis of the literature and proposed research agenda. J Clin Immunol. 2016;36:123–33.CrossRef
3.
Zurück zum Zitat Peshko D, Kulbachinskaya E, Korsunskiy I, Kondrikova E, Pulvirenti F, Quinti I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1929–1957):e5. Peshko D, Kulbachinskaya E, Korsunskiy I, Kondrikova E, Pulvirenti F, Quinti I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1929–1957):e5.
4.
Zurück zum Zitat Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA. 1993;270:1132–3.CrossRef Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA. 1993;270:1132–3.CrossRef
5.
Zurück zum Zitat Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991;18:1411–4.PubMed Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991;18:1411–4.PubMed
6.
Zurück zum Zitat Cleary PD, Morrissey G, Yver A, Oster G. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Qual Life Res. 1994;3:307–15.CrossRef Cleary PD, Morrissey G, Yver A, Oster G. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Qual Life Res. 1994;3:307–15.CrossRef
8.
Zurück zum Zitat Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.CrossRef Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.CrossRef
10.
Zurück zum Zitat Varni JW, Limbers CA. The PedsQL 4.0 generic core scales young adult version: feasibility, reliability and validity in a university student population. J Health Psychol. 2009;14:611–22.CrossRef Varni JW, Limbers CA. The PedsQL 4.0 generic core scales young adult version: feasibility, reliability and validity in a university student population. J Health Psychol. 2009;14:611–22.CrossRef
11.
Zurück zum Zitat Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.CrossRef Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.CrossRef
12.
Zurück zum Zitat Helgeson VS, Holmbeck GN. An introduction to the special issue on peer relations in youth with chronic illness. J Pediatr Psychol. 2015;40:267–71.CrossRef Helgeson VS, Holmbeck GN. An introduction to the special issue on peer relations in youth with chronic illness. J Pediatr Psychol. 2015;40:267–71.CrossRef
13.
Zurück zum Zitat Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.CrossRef Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.CrossRef
14.
Zurück zum Zitat Moore DC, Pellegrino AE. Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797–803.CrossRef Moore DC, Pellegrino AE. Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797–803.CrossRef
15.
Zurück zum Zitat Fioredda F, Lanza T, Gallicola F, Riccardi F, Lanciotti M, Mastrodicasa E, et al. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016;128:2178–81.CrossRef Fioredda F, Lanza T, Gallicola F, Riccardi F, Lanciotti M, Mastrodicasa E, et al. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016;128:2178–81.CrossRef
16.
Zurück zum Zitat Fioredda F, Calvillo M, Lanciotti M, Lanza T, Giunti L, Castagnola E, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer. 2010;54:465–7.CrossRef Fioredda F, Calvillo M, Lanciotti M, Lanza T, Giunti L, Castagnola E, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer. 2010;54:465–7.CrossRef
17.
Zurück zum Zitat Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The severe chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 2006;3:220–31.CrossRef Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The severe chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 2006;3:220–31.CrossRef
18.
Zurück zum Zitat Cheretakis C, Locker D, Dror Y, Glogauer M. Oral health-related quality of life of children with neutropenia. Spec Care Dent. 2007;27:6–11.CrossRef Cheretakis C, Locker D, Dror Y, Glogauer M. Oral health-related quality of life of children with neutropenia. Spec Care Dent. 2007;27:6–11.CrossRef
21.
Zurück zum Zitat Pickett K, Loveman E, Kalita N, Frampton GK, Jones J. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015;19(1–176):v–vi. Pickett K, Loveman E, Kalita N, Frampton GK, Jones J. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015;19(1–176):v–vi.
22.
Zurück zum Zitat Flanagan S, Damery S, Combes G. The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence. Health Qual Life Outcomes. 2017;15:188.CrossRef Flanagan S, Damery S, Combes G. The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence. Health Qual Life Outcomes. 2017;15:188.CrossRef
23.
Zurück zum Zitat Grey M. Coping skills training for youths with diabetes. Diabetes Spectrum. 2011;24:70–5.CrossRef Grey M. Coping skills training for youths with diabetes. Diabetes Spectrum. 2011;24:70–5.CrossRef
24.
Zurück zum Zitat Compas BE, Jaser SS, Dunn MJ, Rodriguez EM. Coping with chronic illness in childhood and adolescence. Annu Rev Clin Psychol. 2012;8:455–80.CrossRef Compas BE, Jaser SS, Dunn MJ, Rodriguez EM. Coping with chronic illness in childhood and adolescence. Annu Rev Clin Psychol. 2012;8:455–80.CrossRef
Metadaten
Titel
Quality of life and patient-reported outcomes in chronic severe neutropenia conditions
Publikationsdatum
15.02.2021
Erschienen in
International Journal of Hematology / Ausgabe 5/2021
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03089-8

Weitere Artikel der Ausgabe 5/2021

International Journal of Hematology 5/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.